Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development
暂无分享,去创建一个
A N Phillips | A. Phillips | M. Youle | C. Loveday | M. Johnson | C Loveday | M Youle | M Johnson | Margaret A. Johnson
[1] A. Phillips,et al. In vivo HIV-1 replicative capacity in early and advanced infection. , 1999, AIDS.
[2] R. Siliciano,et al. Viral Dynamics in HIV-1 Infection , 1998, Cell.
[3] G. M. Ortiz,et al. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection , 2000, AIDS.
[4] M. Youle,et al. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. , 1999, AIDS.
[5] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[6] L. M. Mansky,et al. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.
[7] A. Perelson,et al. Dynamics of HIV infection of CD4+ T cells. , 1993, Mathematical biosciences.
[8] J. Coffin,et al. Linkage disequilibrium test implies a large effective population number for HIV in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[9] T. Leitner,et al. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[10] A. J. Brown,et al. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[11] M A Nowak,et al. Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[12] Sebastian Bonhoeffera,et al. Risks and bene®ts of structured antiretroviral drug therapy interruptions in HIV-1 infection , 2022 .
[13] D Schenzle,et al. A model for AIDS pathogenesis. , 1994, Statistics in medicine.
[14] B Clotet,et al. Prospective Randomized Two‐Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long‐Term Adherence to Highly Active Antiretroviral Therapy , 2000, Journal of acquired immune deficiency syndromes.
[15] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[16] S. Friedman,et al. HIV infection among intravenous drug users: epidemiology and risk reduction. , 1987, AIDS.
[17] P D Griffiths,et al. Population dynamics of HIV within an individual after treatment with zidovudine , 1991, AIDS.
[18] A S Perelson,et al. Modeling HIV infection of CD4+ T-cell subpopulations. , 1994, Journal of theoretical biology.
[19] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[20] Alan S. Perelson,et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.
[21] G. F. Webb,et al. Understanding drug resistance for monotherapy treatment of HIV infection , 1997, Bulletin of mathematical biology.
[22] M A Nowak,et al. Competition between zidovudine‐sensitive and zidovudine‐resistant strains of HIV , 1992, AIDS.
[23] D. Richman,et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.
[24] L M Wahl,et al. Adherence and drug resistance: predictions for therapy outcome , 2000, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[25] S Bonhoeffer,et al. Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[26] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[27] D. Richman,et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. , 1998, JAMA.
[28] Martin A. Nowak,et al. The frequency of resistant mutant virus before antiviral therapy , 1998, AIDS.
[29] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[30] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[31] C. Boucher,et al. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model , 1997, Journal of virology.
[32] A. Phillips. HIV Dynamics: Lessons from the use of antiretrovirals , 1999 .
[33] K. Lange,et al. Mutation Takes No Vacation: Can Structured Treatment Interruptions Increase the Risk of Drug‐Resistant HIV‐1? , 2000, Journal of acquired immune deficiency syndromes.
[34] Alan S. Perelson,et al. Quantitative Image Analysis of HIV-1 Infection in Lymphoid Tissue , 1996, Science.
[35] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[36] P. Kaye. Infectious diseases of humans: Dynamics and control , 1993 .
[37] R. Paredes,et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression , 2000, AIDS.
[38] D. Richman,et al. HIV-1: Gambling on the evolution of drug resistance? , 1997, Nature Medicine.
[39] S. Wain-Hobson. HIV genome variability in vivo , 1989, AIDS.
[40] A S Perelson,et al. Drug concentration heterogeneity facilitates the evolution of drug resistance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[41] M. Zupancic,et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. , 1997, Science.
[42] A. McLean,et al. HIV‐1 dynamics after transient antiretroviral therapy: Implications for pathogenesis and clinical management , 1997, Journal of medical virology.